None listed
Conditions
Interventions
Intervention1: CCP-1/22: Single day oral administration of single dose of 400mg capsules
Intervention2: CCP-2/22: Single day oral administration 500mg 2 capsules
Intervention3: CCP-3/22: Single day or
Sponsors
Lincy Benzy Joshua
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects who are willing to give their written informed consent and comply with the protocol requirements. 2.Females of child bearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening. 3.Subject understands the study procedures, is ready to comply and provide signed informed consent form (ICF) to participate in the study
Exclusion criteria
Exclusion criteria: 1.Subjects who have consumed curcumin containing food 2 days prior to screening 2.Subjects having symptoms of viral infections 3.Pregnant or lactating women. 4.Subjects with known hypersensitivity to the investigational products. 5.Subjects who have participated in any clinical trial in the past 1 month. 6.Any subjects found to have entered in to the study in violation of this protocol or if the subject is uncooperative during the study. 7.Any other condition that in the opinion of the investigator that does not justify the subject’s participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the plasma concentrations of free curcumin in various curcumin products compared to standard curcumin after oral administration and hence to deduce the pharmacokinetics.Timepoint: 0.00h 1.00h, 3.00h, 5.00h, 8.00h | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of study and biomarker analysis.Timepoint: Day 0, Period 1, Period 2,Period 3, Period 4, Period 5, Period 6, Period 7 | — |
Countries
India
Contacts
Public ContactLincy Benzy Joshua
Himgiri Zee University
Outcome results
None listed